NCT01419535View on ClinicalTrials.gov

Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 29, 2011

Primary Completion Date

November 24, 2015

Study Completion Date

November 24, 2015

Conditions
Endocrine DiseaseDiabetes
Interventions
DRUG

Mifepristone

Mifepristone 50mg tablet by mouth every six hours for nine days.

DRUG

Placebo

Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT01419535 - Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults | Biotech Hunter | Biotech Hunter